Vaxcyte Holds Annual Stockholders Meeting on Governance

The latest announcement is out from Vaxcyte ( (PCVX) ).

On June 12, 2025, Vaxcyte, Inc. held its Annual Meeting of Stockholders, where key decisions were made regarding the company’s governance and financial oversight. The meeting resulted in the re-election of three Class II directors, ratification of Deloitte & Touche LLP as the independent auditor for 2025, approval of executive compensation on a non-binding basis, and an amendment to the company’s Certificate of Incorporation to allow for officer exculpation. These decisions are expected to influence Vaxcyte’s operational strategies and governance structure, potentially impacting its market positioning and stakeholder relations.

The most recent analyst rating on (PCVX) stock is a Buy with a $101.00 price target. To see the full list of analyst forecasts on Vaxcyte stock, see the PCVX Stock Forecast page.

Spark’s Take on PCVX Stock

According to Spark, TipRanks’ AI Analyst, PCVX is a Neutral.

Vaxcyte’s stock score reflects its position as a development-stage biotech firm with no revenue, high R&D expenses, and reliance on financing. The technical analysis indicates a bearish trend, while valuation metrics show challenges due to negative earnings. However, the company’s robust pipeline and recent positive clinical results provide optimism for the future. The earnings call and corporate events signal potential for growth, but regulatory and financial challenges remain.

To see Spark’s full report on PCVX stock, click here.

More about Vaxcyte

Vaxcyte, Inc. operates in the biotechnology industry, focusing on the development of vaccines to prevent and treat infectious diseases. The company is committed to advancing its pipeline of vaccine candidates to address significant unmet medical needs.

Average Trading Volume: 2,515,033

Technical Sentiment Signal: Sell

Current Market Cap: $4.43B

For detailed information about PCVX stock, go to TipRanks’ Stock Analysis page.